Systematic review / meta-analysis / 2018
Homocysteine-lowering treatment with B vitamins was not associated with the risk of fracture in an updated meta-analysis of randomized trials.
Researchers conducted a secondary analysis of the AFPPS trial (1,021 participants randomized to 1 mg/day folic acid or placebo) alongside an updated meta-analysis of six RCTs (36,527 participants) evaluating homocysteine-lowering B-vitamin treatment on fracture risk. In the AFPPS, folic acid was not significantly associated with any fracture (RR = 0.95; 95% CI 0.61-1.48) or hip fracture (RR = 0.98; 95% CI 0.25-3.89). In the meta-analysis, interventions with folic acid and/or vitamin B12 yielded a pooled RR of 0.97 (95% CI 0.87-1.09) for any fracture and 1.00 (95% CI 0.81-1.23) for hip fracture. The authors concluded that no association was found between homocysteine-lowering treatment with B vitamins and fracture risk.
- Study type
- Secondary RCT analysis and meta-analysis of RCTs
- Who was studied
- 1,021 trial participants (AFPPS) and 36,527 participants across 6 RCTs in the meta-analysis
- What was measured
- Risk of fractures of any type and hip fracture
THE PAPER
Homocysteine-Lowering Treatment and the Risk of Fracture: Secondary Analysis of a Randomized Controlled Trial and an Updated Meta-Analysis.
Garcia Lopez M, Baron JA, Omsland TK, Søgaard AJ, Meyer HE. JBMR Plus, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.